NBIX - Teva ends enrollment in late-stage Austedo cerebral palsy trial
2023-03-13 12:59:09 ET
- Teva Pharmaceutical Industries ( NYSE: TEVA ) has ended recruitment for a phase 3 trial of Austedo (deutetrabenazine) to treat abnormal involuntary movements with cerebral palsy ("CP").
- Recruitment stopped because the parent study , which was looking at Austedo for dyskinesia in children and adolescents with CP, missed its primary endpoint.
- The terminated trial was set to last 55 weeks.
- RBC Capital Markets analyst Brian Abrahams noted that Neurocrine Biosciences ( NBIX ) is also looking at expanding indications for Ingrezza (valbenazine), including CP.
- Given that Ingrezza has a similar mechanism of action to Austedo, he says this places additional risk for Ingressa CP trial results, which are expected in 2024.
- Read why seeking Alpha contributor The Value Investor recently initiated Teva ( TEVA ) with a buy.
For further details see:
Teva ends enrollment in late-stage Austedo cerebral palsy trial